XBiotech Inc. Files 8-K on Security Holder Votes
Ticker: XBIT · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1626878
| Field | Detail |
|---|---|
| Company | Xbiotech Inc. (XBIT) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
Related Tickers: XBI
TL;DR
XBiotech filed an 8-K for shareholder votes - check for updates on corporate actions.
AI Summary
XBiotech Inc. filed an 8-K on June 20, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's corporate structure, including its state of incorporation (British Columbia, Canada) and principal executive offices in Austin, Texas.
Why It Matters
This filing indicates that XBiotech Inc. is engaging with its shareholders on important corporate decisions, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure regarding shareholder votes and does not immediately present new financial or operational risks.
Key Players & Entities
- XBiotech Inc. (company) — Registrant
- June 20, 2024 (date) — Date of Report
- British Columbia, Canada (location) — State of Incorporation
- Austin, TX (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of XBiotech Inc.'s security holders?
The filing states that the 8-K is being filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and is a "CURRENT REPORT" reporting "Submission of Matters to a Vote of Security Holders." However, the specific details of the matters voted upon are not included in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 20, 2024.
What is XBiotech Inc.'s state of incorporation?
XBiotech Inc.'s state of incorporation is British Columbia, Canada.
Where are XBiotech Inc.'s principal executive offices located?
XBiotech Inc.'s principal executive offices are located at 5217 Winnebago Ln, Austin, TX 78744.
What is the Commission File Number for XBiotech Inc.'s 8-K filings?
The Commission File Number for XBiotech Inc. is 001-37347.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 8.6 · Accepted 2024-06-20 12:57:05
Filing Documents
- f8k_062024.htm (8-K) — 23KB
- 0001171843-24-003541.txt ( ) — 182KB
- xbit-20240620.xsd (EX-101.SCH) — 3KB
- xbit-20240620_lab.xml (EX-101.LAB) — 33KB
- xbit-20240620_pre.xml (EX-101.PRE) — 22KB
- f8k_062024_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The annual meeting of the stockholders of XBiotech Inc. (the "Company") was held on June 20, 2024. The matters that were voted upon at the meeting, and the number of votes cast for and against, as well as the number of abstentions and broker non-votes as to each such matter, are set forth below. Stockholders voted in accordance with the Board of Directors' recommendations on each matter and voted to (1) elect five nominees for director; (2) ratify the selection by the Audit Committee of the Board of Directors of Whitley Penn LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Proposal #1 Election of five members of the Board of Directors For Abstain Broker Non-Votes John Simard 9,032,922.58 14,388.00 2,573,795.00 Jan-Paul Waldin 7,407,212.58 1,635,148.00 2,578,745.00 W. Thorpe McKenzie 8,485,018.58 558,511.00 2,577,576.00 Donald MacAdam 8,817,755.58 225,774.00 2,577,576.00 Peter Libby 9,040,330.58 6,980.00 2,573,795.00 Proposal #2 Ratification of the selection of Whitley Penn LLP as the Company's independent registered public accounting firm for the fiscal year ending 2024 For Against Abstain Broker Non-Votes 11,411,235.58 146,216.00 63,654.00 0
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 20, 2024 XBIOTECH INC. By: /s/John Simard John Simard Chief Executive Officer and President